What is claimed is:

1. A compound of formula (I):



(I)

R^1 and R^2 are each independently selected from the group consisting of

a) H, C_{1-7}alkyl, C_{2-7}alkenyl, C_{2-7}alkynyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkenyl, benzo-fusedC_{4-7}cycloalkyl where the point of attachment is a carbon atom adjacent to the ring junction, C_{3-7}cycloalkylC_{1-7}alkyl,

b) naphthyl-(CR^s_2)-, benzoylC_{0-3}alkyl-(CR^s_2)-, phenyl, said phenyl optionally fused at two adjacent carbon atoms to R^f, phenyl-(CR^s_2)-, said phenyl optionally fused at two adjacent carbon atoms to R^f,

R^f is a linear 3- to 5-membered hydrocarbon moiety having 0 or 1 unsaturated bonds and having 0, 1 or 2 carbon members which is a carbonyl,

c) Ar^6-(CR^s_2)-, where Ar^6 is a 6-membered heteroaryl having carbon as a point of attachment, having 1 or 2 heteroatom members which are -N= and optionally benzo fused or pyrido fused,

d) Ar^5-(CR^s_2)-, where Ar^5 is a 5-membered heteroaryl having carbon as a point of attachment, having 1 heteroatom member selected from the group consisting of O, S, >NH or $>NC_{1-4}$alkyl, having 0 or 1 additional heteroatom member which is -N= and optionally benzo fused or pyrido fused,

e) Ar^{6-6}-(CR^s_2)-, where Ar^{6-6} is phenyl having the point of attachment and fused to a 6-membered heteroaryl having 1 or 2 heteroatom members which are –N=,

f) Ar^{6-5}-(CR^s_2)-, where Ar^{6-5} is phenyl having the point of attachment and fused to a 5-membered heteroaryl having 1 heteroatom member selected from the group consisting of O, S, >NH or >NC_{1-4}alkyl and having 0 or 1 additional heteroatom member which is -N=,

g) C_{1-4}alkylO- and HSC_{1-4}alkyl,

where R^1 and R^2 are not simultaneously H and, except in positions where R^s is indicated, each of a) to g) is substituted with 0, 1, 2, or 3 of R^q,

R^q is independently selected from the group consisting of C_{1-4}alkyl, hydroxy, fluoro, chloro, bromo, iodo, trifluoromethyl, aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkyl, diC_{1-4}alkylaminoC_{1-4}alkyl, HO-C_{1-4}alkyl, C_{1-4}alkylO-C_{1-4}alkyl, HS-C_{1-4}alkyl, C_{1-4}alkylS-C_{1-4}alkyl, C_{1-4}alkoxy and C_{1-4}alkylS-,

R^s is independently selected from the group consisting of hydrogen, C_{1-4}alkyl, trifluoromethyl, aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkyl, diC_{1-4}alkylaminoC_{1-4}alkyl, HO-C_{1-4}alkyl, HS-C_{1-4}alkyl, C_{1-4}alkylS-C_{1-4}alkyl and phenyl;

or, alternatively,

R^1 and R^2 may be taken together with the nitrogen to which they are attached and are selected from the group consisting of

i) 10-Oxa-4-aza-tricyclo[5.2.1.$0^{2,6}$]dec-4-yl, optionally mono- or di-substituted with R^p,

R^p is independently selected from the group consisting of hydroxy, C_{1-4}alkyl, hydroxyC_{1-4}alkyl, phenyl, mono-, di- or tri-halo substituted phenyl and hydroxyphenyl,

ii) a 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR^p, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, optionally having one carbon member which forms a bridge and having 0, 1 or 2 substituents R^p,

iii) a benzo fused 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the

nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR^p, having 0 or 1 additional unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, having 0, 1, 2, or 3 halo substituents on the benzene ring only and having 0, 1 or 2 substituents R^p,

iv) a 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR^p, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and optionally having one carbon member which forms a bridge, the heterocyclic ring fused at two adjacent carbon atoms forming a saturated bond or an adjacent carbon and nitrogen atom forming a saturated bond to a 4-7 membered hydrocarbon ring, having 0 or 1 possibly additional heteroatom member, not at the ring junction, selected from O, S, -N=, >NH or >NR^p, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and having 0, 1 or 2 substituents R^p;

v) 8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl, optionally having 0, 1 or 2 substituents R^p;

R^a is, independently, selected from the group consisting of -C_{1-6}alkyl, -C_{2-6}alkenyl, -C_{3-6}cycloalkyl, phenyl, furanyl, thienyl, benzyl, pyrrol-1-yl, -OH, -OC_{1-6}alkyl, -OC_{3-6}cycloalkyl, -Ophenyl, -Obenzyl, -SH, -SC_{1-6}alkyl, -SC_{3-6}cycloalkyl, -Sphenyl, -Sbenzyl, -CN, -NO_2, -N(R^y)R^z (wherein R^y and R^z are independently selected from H, C_{1-4}alkyl or C_{1-6}cycloalkylC_{1-4}alkyl), -(C=O)C_{1-4}alkyl, -SCF_3, halo, -CF_3, -OCF_3, and -COOC_{1-4}alkyl, or, alternatively, two adjacent R^a, may be taken together with the carbons of attachment to form a fused ring and selected from the group consisting of phenyl, pyridyl and pyrimidinyl;

R^b is, independently, selected from the group consisting of -C_{1-4}alkyl and halogen;

and enantiomers, diastereomers, hydrates, solvates and pharmaceutically acceptable salts, esters and amides thereof,.

with the proviso that the compound of formula I cannot include compounds in which:

A) one of R^1 and R^2 is phenyl substituted with 1, 2, or 3 of halo, or

B) a compound of the formula:



and



2. The compound of claim 1 wherein R^1 and R^2 are, independently, selected from the group consisting of

a) H, C_{1-7}alkyl, ethenyl, propenyl, butenyl, ethynyl, propynyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, indan-1-yl, 1,2,3,4-tetrahydro-naphthalen-1-yl, 6,7,8,9-tetrahydro-5H-benzocyclohepten-5-yl, cyclobutylC_{1-4}alkyl, cyclopentylC_{1-4}alkyl, cyclohexylC_{1-4}alkyl, cycloheptylC_{1-4}alkyl,

b) phenyl, 6,7,8,9-tetrahydro-5H-benzocyclohepten-1,2,3 or 4-yl, optionally 5,6,7,8 or 9 oxo substituted, 5,6,7,8-tetrahydro-naphthalen-1,2,3 or 4-yl, optionally 5,6,7 or 8-oxo-substituted, benzyl, 6,7,8,9-tetrahydro-5H-benzocyclohepten-1,2,3 or 4-ylmethyl, optionally 5,6,7,8 or 9 oxo substituted, 5,6,7,8-tetrahydro-naphthalen-1,2,3 or 4-ylmethyl, optionally 5,6,7 or 8 oxo substituted, 1-phenyleth-1-yl, benzhydryl, naphthylmethyl, benzoylmethyl, 1-benzoyleth-1-yl,

c) pyridylmethyl, pyrazinylmethyl, pyrimidinylmethyl, pyridazinylmethyl, quinolin-2,3 or 4-ylmethyl, isoquinolin-1,3 or 4-ylmethyl, quinazolin-2 or 4-ylmethyl, quinoxalin-2 or 3-ylmethyl,

d) furanylmethyl, thiophenylmethyl, 1-(H or C_{1-4}alkyl)pyrrolylmethyl, oxazolylmethyl, thiazolylmethyl, pyrazolylmethyl, imidazolylmethyl, isoxazolylmethyl, isothiazolylmethyl, benzofuran-2 or 3-ylmethyl,

benzothiophen-2 or 3-ylmethyl, 1-(H or C_{1-4}alky)-1H-indol-2 or 3-ylmethyl, 1-(H or C_{1-4}alkyl)-1H-benzimidazol-2-ylmethyl, benzooxazol-2-ylmethyl, benzothiazol-2-ylmethyl,

e) quinolin-5,6,7 or 8-ylmethyl, isoquinolin-5,6,7 or 8-ylmethyl, quinazolin-5,6,7 or 8-ylmethyl, quinoxalin-5,6,7 or 8-ylmethyl,

f) benzofuran-4,5,6 or 7-ylmethyl, benzothiophen-4,5,6 or 7-ylmethyl, 1-(H or C_{1-4}alky)-1H-indol-4,5,6 or 7-ylmethyl, 1-(H or C_{1-4}alkyl)-1H-benzimidazol-4,5,6 or 7-ylmethyl, benzooxazol-4,5,6 or 7-ylmethyl, benzothiazol-4,5,6 or 7-ylmethyl,

g) C_{1-4}alkylO- and HSC_{1-4}alkyl,

where each of a) to g) is substituted with 0, 1, 2, or 3 of R^q.

3. The compound of claim 1 wherein R^1 and R^2 are, independently, selected from the group consisting of hydrogen, methyl, ethyl, butyl, hexyl, phenyl, 6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl, optionally 5,6,7,8 or 9 oxo substituted, benzyl, 1-phenyleth-1-yl, furanylmethyl, benzoylethyl, 1-benzoyleth-1-yl, methylO-, cyclohexyl, cyclohexylmethyl, pyridylmethyl, naphthylmethyl, 1,2,3,4-tetrahydro-naphthalen-1-yl, benzhydryl, where each member is substituted with 0, 1, 2, or 3 of R^q.

4. The compound of claim 1 wherein R^1 and R^2 are, independently, selected from the group consisting of hydrogen, methyl, ethyl, butyl, phenyl, benzyl, 2-bromobenzyl, 2-chlorobenzyl, 4-chlorobenzyl, 2,4-dichlorobenzyl, 3,4-dichlorobenzyl, 2,6-dichlorobenzyl, 2,4,6-trichlorobenzyl, 2-fluorobenzyl, 4-fluorobenzyl, 2,4-difluorobenzyl, 2,6-difluorobenzyl, 2,4,6-trifluorobenzyl, 2-chloro-4-fluorobenzyl, 2-fluoro-4-bromobenzyl, 2-fluoro-4-chlorobenzyl, 2-methylbenzyl, 2-methylsulfanylbenzyl, 2-trifluoromethylbenzyl, 1-phenyleth-1-yl, 1-phenylprop-1-yl, 1-(4-bromophenyl)eth-1-yl, 1-(4-fluorophenyl)eth-1-yl, 1-(2,4-dibromophenyl)eth-1-yl, 1-(2,4-dichlorophenyl)eth-1-yl, 1-(3,4-dichlorophenyl)eth-1-yl, 1-(2,4-difluorophenyl)eth-1-yl, 1-(4-methylphenyl)eth-1-yl, 1-methyl-1-phenyleth-1-yl, 1-phenyl-2-dimethylaminoeth-1-yl, 1-benzoyleth-1-yl, cyclohexyl, 1-cyclohexyleth-1-yl, furan-2-ylmethyl, naphth-1-ylmethyl, methoxy,

methylthioethyl, 6-methyl-6-hydroxyhept-2-yl, 1,2,3,4-tetrahydro-naphthalen-1-yl, 1-phenyl-2-hydroxyeth-1-yl, benzhydryl, 4-hydroxymethylpiperidin-1-yl, and 9-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl.

5. The compound of claim 1 wherein one of R^1 and R^2 is H or C_{1-4}alkyl where the other is not H or C_{1-4}alkyl.

6. The compound of claim 1 wherein one of R^1 and R^2 is H, methyl or ethyl.

7. The compound of claim 1 wherein, at least one of R^1 and R^2 are, independently, selected from the groups consisting of



where R^s is not hydrogen, said phenyl is optionally fused at two adjacent carbon atoms to R^f and, except in positions where R^s is indicated, each member is substituted with 0, 1, 2, or 3 of R^q.

8. The compound of claim 1 wherein R^f is selected from the group consisting of $-CH_2CH_2CH_2-$, $-CH_2CH_2CH_2CH_2-$, $-CH_2CH_2CH_2CH_2CH_2-$ and $-(C=O)CH_2CH_2CH_2-$.

9. The compound of claim 1 wherein R^s is selected from the group consisting of hydrogen, methyl, ethyl, propyl, trifluoromethyl, aminomethyl, methylaminomethyl, dimethylaminomethyl, hydroxymethyl, methoxymethyl, thiomethyl, methylthiomethyl and phenyl.

10. The compound of claim 1 wherein R^s is selected from the group consisting of H, methyl, ethyl, hydroxymethyl and dimethylaminomethyl.

11. The compound of claim 1 wherein R^q is selected from the group consisting of methyl, ethyl, propyl, t-butyl, hydroxy, fluoro, chloro, bromo, iodo,

trifluoromethyl, aminomethyl, methylaminomethyl, dimethylaminomethyl, hydroxymethyl, methoxymethyl, thiomethyl, methylthiomethyl, methoxy, ethoxy, methylmercapto and ethylmercapto.

12. The compound of claim 1 wherein R^q is selected from the group consisting of methyl, hydroxy, fluoro, chloro, bromo, iodo and trifluoromethyl.

13. The compound of claim 1 wherein, R^1 and R^2 taken together with the nitrogen to which they are attached are selected from the group consisting of

i) 10-Oxa-4-aza-tricyclo[5.2.1.$0^{2,6}$]dec-4-yl,

ii) 2-pyrrolin-1-yl, 3-pyrrolin-1-yl, pyrrolidin-1-yl, 2-imidazolin-1-yl, 3-(H or R^p)imidazolidin-1-yl, piperidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, 3-(H or R^p)piperazin-1-yl, azepan-1-yl, thiazolidin-3-yl, oxazolidin-3-yl, 2,5-dihydro-pyrrol-1-yl, azetidin-1-yl, where each member of ii) in each ring has 0 or 1 unsaturated bond and has 0, 1 or 2 carbon members which is a carbonyl,

iii) 3,4-dihydro-2H-quinolin-1-yl, 3,4-dihydro-2H-quinolin-2-yl, 2,3-dihydro-indol-1-yl, 1,3-dihydro-isoindol-2-yl, 1-oxo-1,3-dihydro-isoindol-2-yl, tetrahydro-benzo[b, c or d]azepin-1-yl, where each member of iii) in each ring has 0 or 1 unsaturated bond and has 0, 1 or 2 carbon members which are a carbonyl,

iv) decahydro-quinolin-1-yl, octahydro-isoquinolin-2-yl, octahydro-[1 or 2]pyrindin-1 or 2-yl, octahydro-indol-1-yl, octahydro-isoindol2-yl, hexahydro-cyclopenta[b]pyrrol-1-yl, hexahydro-cyclopenta[c]pyrrol-2-yl, (5,6,7 or 8-H or R^p)-decahydro-[1,5 or 1,6 or 1,7 or 1,8]naphthyridin-1-yl, (5,6,7 or 8-H or R^p)-decahydro-[2,5 or 2,6 or 2,7 or 2,8]naphthyridin-2-yl, 1-H or R^p-octahydro-pyrrolo[2,3-c]pyridin-6-yl, 2-H or R^p-octahydro-pyrrolo[3,4-c]pyridin-5-yl, 1-H or R^p-octahydro-pyrrolo[3,2-c]pyridin-5-yl, 1-H or R^p-octahydro-pyrrolo[2,3-b]pyridin-7-yl, 6-H or R^p-octahydro-pyrrolo[3,4-b]pyridin-1-yl, 1-H or R^p-octahydro-pyrrolo[3,2-b]pyridin-4-yl, 5-H or R^p-octahydro-pyrrolo[3,4-c]pyridin-2-yl, 6-H or R^p-octahydro-pyrrolo[2,3-c]pyridin-1-yl, 1-H or R^p-octahydro-pyrrolo[3,4-b]pyridin-6-yl, 7-H or R^p-octahydro-pyrrolo[2,3-b]pyridin-1-yl, octahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl, where each member of iv) in each ring has 0, 1 or 2 carbon members which is a carbonyl, each ring of

attachment has 0 or 1 unsaturated bonds and each secondary ring has 0, 1 or 2 unsaturated bonds,

v) 8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl,

where each member of i), ii), iii), iv) or v) is further substituted with 0, 1 or 2 of R^p.

14. The compound of claim 1 wherein, R^1 and R^2 taken together with the nitrogen to which they are attached are selected from the group consisting of 10-oxa-4-aza-tricyclo[5.2.1.$0^{2,6}$]dec-4-yl, 2-pyrrolin-1-yl, 3-pyrrolin-1-yl, pyrrolidin-1-yl, 2-imidazolin-1-yl, imidazolidin-1-yl, piperidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, piperazin-1-yl, azepan-1-yl, thiazolidin-3-yl, oxazolidin-3-yl, 2,5-dihydro-pyrrol-1-yl, 8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl, azetidin-1-yl, octahydro-quinolin-1-yl, 3,4-dihydro-2H-quinolin-1-yl, 3,4-dihydro-2H-quinolin-2-yl, where each member is further substituted with 0, 1 or 2 of R^p.

15. The compound of claim 1 wherein R^1 and R^2 taken together with the nitrogen to which they are attached are selected from the group consisting of 1-methyl-10-oxa-4-aza-tricyclo[5.2.1.$0^{2,6}$]dec-4-yl, azetidin-1-yl, pyrrolidin-1-yl, 2-hydroxymethylpyrrolidin-1-yl, 2,4-dimethyl-3-ethylpyrrolidin-1-yl, piperidin-1-yl, 2-methylpiperidin-1-yl, 4-hydroxymethylpiperidin-1-yl, 4-phenylpiperidin-1-yl, azepan-1-yl, 4-(2-hydroxyphenyl)piperazin-1-yl, morpholin-4-yl, octahydro-isoquinolin-2-yl, decahydro-quinolin-1-yl, thiazolidin-3-yl, 2,5-dimethyl-2,5-dihydro-pyrrol-1-yl, 8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl and 3,4-dihydro-2H-quinolin-2-yl.

16. The compound of claim 1 wherein R^p is selected from the group consisting of hydroxy, methyl, ethyl, propyl, hydroxymethyl, hydroxyethyl, phenyl, p-halophenyl, m-halophenyl, o-halophenyl, and p-hydroxyphenyl.

17. The compound of claim 1 wherein R^p is selected from the group consisting of hydroxy, methyl, ethyl, hydroxymethyl, hydroxyethyl, phenyl, mono-fluorosubstituted phenyl and mono-chlorosubstituted phenyl.

18. The compound of claim 1 wherein R^a is selected from the group consisting of methyl, ethyl, propyl, ethenyl, propenyl, cyclopropyl, cyclobutyl, phenyl, furanyl, thienyl, pyrrol-1-yl, benzyl, hydroxy, methoxy, ethoxy, propoxy, cyclopropoxy, cyclobutoxy, cyclopentoxy, phenoxy, benzoxy, -SH, -Smethyl, -Sethyl, -S-t-butyl, -Scyclopropyl, -Sphenyl, -Sbenzyl, $-NO_2$, -CN, amino, dimethylamino, (cyclohexylmethyl)amino, acetyl, $-SCF_3$, I, F, Cl, Br, $-CF_3$, $-OCF_3$ and carboxymethyl.

19. The compound of claim 1 wherein there is one R^a.

20. The compound of claim 1 wherein there is one R^a positioned on the ring para to the amide substituent.

21. The compound of claim 1 wherein two adjacent R^a are taken together with the carbons of attachment to form a fused ring.

22. The compound of claim 21 wherein the fused ring is benzo.

23. The compound of claim 1 wherein R^c is selected from the group consisting of nitro, F, Cl, Br, fused benzo, I, CF_3, methoxy, ethoxy, propoxy, i-propoxy, ethenyl, cyclopentoxy, 2-propenyl, phenyl, furanyl, thienyl, amino, pyrrol-1-yl, dimethylamino, (cyclohexylmethyl)amino, -Smethyl, -Sethyl, -S-t-butyl, -Sbenzyl, $-SCF_3$, i-propyl and methyl.

24. The compound of claim 1 wherein R^b is absent or selected from the group consisting of methyl, ethyl, I, F, Cl and Br.

25. The compound of claim 1 wherein R^b is absent.

26. The compound of claim 1 wherein said pharmaceutically acceptable salts are selected from the group consisting of hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, trifluoroacetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactiobionate and laurylsulfonate salts.

27. A compound selected from the group consisting of:

EX	Compound
1	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(piperidine-1-carbonyl)-phenyl]-amide;
2	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-nitro-2-(piperidine-1-carbonyl)-phenyl]-amide;
3	Benzo[1,2,5]thiadiazole-4-sulfonic acid [4-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide;
4	Benzo[1,2,5]thiadiazole-4-sulfonic acid [3-(piperidine-1-carbonyl)-naphthalen-2-yl]-amide;
5	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide;
6	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-iodo-2-(piperidine-1-carbonyl)-phenyl]-amide;
10	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-methoxy-2-(piperidine-1-carbonyl)-phenyl]-amide;
11	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-ethoxy-2-(piperidine-1-carbonyl)-phenyl]-amide;
12	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-propoxy-phenyl]-amide;
13	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-isopropoxy-2-(piperidine-1-carbonyl)-phenyl]-amide;
14	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-cyclopentyloxy-2-(piperidine-1-carbonyl)-phenyl]-amide;

15	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-vinyl-phenyl]-amide;
16	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-allyl-2-(piperidine-1-carbonyl)-phenyl]-amide;
17	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-ethyl-2-(piperidine-1-carbonyl)-phenyl]-amide;
18	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-propyl-phenyl]-amide;
19	Benzo[1,2,5]thiadiazole-4-sulfonic acid [4-(piperidine-1-carbonyl)-biphenyl-3-yl]-amide;
20	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-furan-2-yl-2-(piperidine-1-carbonyl)-phenyl]-amide;
21	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-furan-3-yl-2-(piperidine-1-carbonyl)-phenyl]-amide;
22	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-thiophen-2-yl-phenyl]-amide;
23	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-thiophen-3-yl-phenyl]-amide;
24	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-amino-2-(piperidine-1-carbonyl)-phenyl]-amide;
25	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-pyrrol-1-yl-phenyl]-amide;
26	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-dimethylamino-2-(piperidine-1-carbonyl)-phenyl]-amide;
27	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-(cyclohexylmethyl-amino)-2-(piperidine-1-carbonyl)-phenyl]-amide;
28	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-methylsulfanyl-2-(piperidine-1-carbonyl)-phenyl]-amide;
29	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-ethylsulfanyl-2-(piperidine-1-carbonyl)-phenyl]-amide;
30	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-isobutylsulfanyl-2-(piperidine-1-carbonyl)-phenyl]-amide;

31	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-benzylsulfanyl-2-(piperidine-1-carbonyl)-phenyl]-amide;
32	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-trifluoromethyl-phenyl]-amide;
33	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-fluoro-2-(piperidine-1-carbonyl)-phenyl]-amide;
34	Benzo[1,2,5]thiadiazole-4-sulfonic acid [3-chloro-2-(piperidine-1-carbonyl)-phenyl]-amide;
35	Benzo[1,2,5]thiadiazole-4-sulfonic acid [4,5-dibromo-2-(piperidine-1-carbonyl)-phenyl]-amide;
36	Benzo[1,2,5]thiadiazole-4-sulfonic acid [4,5-dichloro-2-(piperidine-1-carbonyl)-phenyl]-amide;
37	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-isopropyl-2-(piperidine-1-carbonyl)-phenyl]-amide;
44	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-methyl-2-(piperidine-1-carbonyl)-phenyl]-amide;
54	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(1-methyl-10-oxa-4-aza-tricyclo[5.2.1.$0^{2,6}$]decane-4-carbonyl)-phenyl]-amide;
60	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(pyrrolidine-1-carbonyl)-phenyl]-amide;
62	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(4-hydroxymethyl-piperidine-1-carbonyl)-phenyl]-amide;
63	Benzo[1,2,5]thiadiazole-4-sulfonic acid {5-chloro-2-[4-(2-hydroxy-phenyl)-piperazine-1-carbonyl]-phenyl}-amide;
64	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(2-hydroxymethyl-pyrrolidine-1-carbonyl)-phenyl]-amide;
66	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(2,5-dimethyl-2,5-dihydro-pyrrole-1-carbonyl)-phenyl]-amide;
68	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(azepane-1-carbonyl)-5-chloro-phenyl]-amide;
70	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(2-methyl-piperidine-1-carbonyl)-phenyl]-amide;

71	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(octahydro-isoquinoline-2-carbonyl)-phenyl]-amide;
72	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(3-ethyl-2,4-dimethyl-pyrrolidine-1-carbonyl)-phenyl]-amide;
73	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(4-phenyl-piperidine-1-carbonyl)-phenyl]-amide;
75	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(octahydro-quinoline-1-carbonyl)-phenyl]-amide;
78	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(azetidine-1-carbonyl)-5-chloro-phenyl]-amide;
79	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(thiazolidine-3-carbonyl)-phenyl]-amide;
80	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(1,2,3,4-tetrahydro-naphthalene-2-carbonyl)-phenyl]-amide;
89	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocine-3-carbonyl)-phenyl]-amide;
90	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(2,5-dimethyl-pyrrolidine-1-carbonyl)-phenyl]-amide;
91	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(morpholine-4-carbonyl)-phenyl]-amide;
137	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-bromo-2-(morpholine-4-carbonyl)-phenyl]-amide;
138	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-iodo-2-(morpholine-4-carbonyl)-phenyl]-amide;
139	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-methyl-2-(morpholine-4-carbonyl)-phenyl]-amide;
140	7-Methyl-benzo[1,2,5]thiadiazole-4-sulfonic acid [5-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide;
177	5-Methyl-benzo[1,2,5]thiadiazole-4-sulfonic acid [5-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide;

178	7-Bromo-benzo[1,2,5]thiadiazole-4-sulfonic acid [5-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide; and
182	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(1,3,4,5-tetrahydro-benzo[c]azepine-2-carbonyl)-phenyl]-amide.

28. A compound selected from the group consisting of:

EX	Compound
7	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-chloro-N-methyl-benzamide;
8	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-bromo-N-methyl-benzamide;
9	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-iodo-N-methyl-benzamide;
38	3-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-naphthalene-2-carboxylic acid (4-fluoro-benzyl)-methylamide;
39	(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-difluoro-phenyl)-ethyl]-4-trifluoromethylbenzamide;
40	(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-difluorophenyl)-ethyl]-4-fluorobenzamide;
41	(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-difluoro-phenyl)-ethyl]-benzamide;
42	(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-dichlorophenyl)-ethyl]-4-methylbenzamide;
43	(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-[1-(2,4-dichloro-phenyl)-ethyl]-benzamide;
45	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-chloro-benzyl)-benzamide;
46	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-chloro-N-(5-hydroxy-1,5-dimethylhexyl)benzamide;
47	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-methylsulfanyl-benzyl)benzamide;

48	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-dimethylamino-1-phenyl-ethyl)-N-methylbenzamide TFA salt;
49	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-chloro-N-ethyl-benzamide;
50	N-Benzhydryl-2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-methyl-benzamide;
51	(*S*) 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-methyl-N-(1-phenyl-ethyl)-benzamide;
52	(*R*) 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-methyl-N-(1-phenyl-ethyl)-benzamide;
53	(*R*) 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1-phenyl-ethyl)-benzamide;
55	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-bromo-2-fluoro-benzyl)-4-chloro-benzamide;
56	(*R*) 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-bromo-phenyl)-ethyl]-4-chloro-benzamide;
57	(*R*) 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1-p-tolyl-ethyl)-benzamide;
58	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-methyl-N-phenyl-benzamide;
59	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-butyl-4-chloro-benzamide;
61	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(4-fluoro-phenyl)-ethyl]-benzamide;
65	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N,N-diethyl-benzamide;
67	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-furan-2-ylmethyl-N-methyl-benzamide;
69	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-methyl-N-naphthalen-1-ylmethyl-benzamide;
74	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-cyclohexyl-N-methyl-benzamide;

76	*(R)*-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1-cyclohexyl-ethyl)-benzamide;
77	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(9-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-benzamide;
81	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4-difluoro-benzyl)-benzamide;
82	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-fluoro-benzyl)-benzamide;
83	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4-dichloro-benzyl)-benzamide;
84	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(3,4-dichloro-benzyl)-benzamide;
85	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(4-chloro-benzyl)-benzamide;
86	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(4-fluoro-benzyl)-benzamide;
87	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1,2,3,4-tetrahydro-naphthalen-1-yl)-benzamide;
88	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(3,4-dichloro-phenyl)-ethyl]-benzamide;
92	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(4-chloro-2-fluoro-benzyl)-benzamide;
93	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-chloro-4-fluoro-benzyl)-benzamide;
94	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-trifluoromethyl-benzyl)-benzamide;
95	(S)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-hydroxy-1-phenyl-ethyl)-benzamide;
96	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-bromo-benzyl)-4-chloro-benzamide;
97	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1-phenyl-propyl)-benzamide;

98	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-methyl-benzyl)-benzamide;
99	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-bromo-benzyl)-4-chloro-benzamide;
100	*(R)*-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-N-methyl-N-(1-phenyl-ethyl)-benzamide;
101	*(R)*-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-methyl-N-(1-phenyl-ethyl)-benzamide;
102	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4-dichloro-benzyl)-benzamide;
103	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-4-iodo-N-methyl-benzamide;
104	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-4-iodo-N-methyl-benzamide;
105	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-fluoro-phenyl)-ethyl]-4-iodo-N-methyl-benzamide;
106	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluoro-benzyl)-4-iodo-N-methyl-benzamide;
107	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4-dichloro-benzyl)-N-methyl-benzamide;
108	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-chloro-4-fluoro-benzyl)-N-methyl-benzamide;
109	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4-difluoro-benzyl)-N-methyl-benzamide;
110	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2-chloro-4-fluoro-benzyl)-N-methyl-benzamide;
111	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4-difluoro-benzyl)-N-methyl-benzamide;
112	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[1-(4-fluoro-phenyl)-ethyl]-N-methyl-benzamide;
113	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4-dichloro-benzyl)-N-methyl-benzamide;

114	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-4-iodo-benzamide;
115	*(R)*-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-N-(1-phenyl-ethyl)-benzamide;
116	*(R)*-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(1-phenyl-ethyl)-benzamide;
117	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-methoxy-N-methyl-benzamide;
118	*(R)*-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-methyl-N-(1-phenyl-ethyl)-benzamide;
119	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-benzamide;
120	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-4-methyl-benzamide;
121	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2,4-dichloro-benzyl)-benzamide;
122	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-N-methyl-benzamide;
123	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-4,N-dimethyl-benzamide;
124	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2,4-dichloro-benzyl)-N-methyl-benzamide;
125	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2,4-difluoro-benzyl)-N-methyl-benzamide;
126	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluoro-benzyl)-N-methyl-benzamide;
127	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluoro-benzyl)-4,N-dimethyl-benzamide;
128	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2-chloro-4-fluoro-benzyl)-N-methyl-benzamide;
129	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(4-fluoro-phenyl)-ethyl]-N-methyl-benzamide;

130	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-[1-(4-fluoro-phenyl)-ethyl]-N-methyl-benzamide;
131	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4-difluoro-benzyl)-benzamide;
132	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-4-iodo-benzamide;
133	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-4-methyl-benzamide;
134	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2,4-difluoro-benzyl)-benzamide;
135	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-N-methyl-benzamide;
136	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4,N-dimethyl-benzamide;
141	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,6-difluoro-benzyl)-benzamide;
142	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,6-dichloro-benzyl)-benzamide;
143	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4,6-trifluoro-benzyl)-benzamide;
144	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4,6-trichloro-benzyl)-benzamide;
145	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1-methyl-1-phenyl-ethyl)-benzamide;
146	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(2,4-dichloro-phenyl)-ethyl]-benzamide;
147	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(2,4-difluoro-phenyl)-ethyl]-benzamide;
148	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,6-difluoro-benzyl)-benzamide;
149	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,6-dichloro-benzyl)-benzamide;

150	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4,6-trifluoro-benzyl)-benzamide;
151	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4,6-trichloro-benzyl)-benzamide;
152	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2-chloro-4-fluoro-benzyl)-benzamide;
153	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(1-methyl-1-phenyl-ethyl)-benzamide;
154	*(R)*-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[1-(2,4-dichloro-phenyl)-ethyl]-benzamide;
155	(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-benzamide;
156	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-N-(2,4,6-trifluoro-benzyl)-benzamide;
157	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-N-(2,4,6-trichloro-benzyl)-benzamide;
158	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluoro-benzyl)-4-iodo-benzamide;
159	*(R)*-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-dichloro-phenyl)-ethyl]-4-iodo-benzamide;
160	*(R)*-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-difluoro-phenyl)-ethyl]-4-iodo-benzamide;
161	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,6-dichloro-benzyl)-benzamide;
162	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4,6-trifluoro-benzyl)-benzamide;
163	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluoro-benzyl)-benzamide;
164	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-methyl-N-(2,4,6-trifluoro-benzyl)-benzamide;
165	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-methyl-N-(2,4,6-trichloro-benzyl)-benzamide;

166	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluoro-benzyl)-4-methyl-benzamide;
167	*(R)*-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-difluoro-phenyl)-ethyl]-4-methyl-benzamide;
168	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2-chloro-4-fluoro-benzyl)-benzamide;
169	*(R)*-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-[1-(2,4-difluoro-phenyl)-ethyl]-benzamide;
170	*(R)*-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,N-dimethyl-N-(1-phenyl-ethyl)-benzamide;
171	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-N-methyl-benzamide;
172	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-4,N-dimethyl-benzamide;
173	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-fluoro-phenyl)-ethyl]-N-methyl-benzamide;
174	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-fluoro-phenyl)-ethyl]-4,N-dimethyl-benzamide;
175	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-benzamide;
176	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-5-chloro-N-methyl-benzamide;
180	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(4-fluoro-benzyl)-N-methyl-benzamide;
181	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(4-chloro-benzyl)-N-methyl-benzamide;
183	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[1-(4-fluoro-phenyl)-ethyl]-benzamide;
184	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(4-fluoro-benzyl)-N-methyl-benzamide;
185	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(4-chloro-benzyl)-N-methyl-benzamide;

186	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,6-dichloro-benzyl)-4-iodo-benzamide;
187	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-chloro-phenyl)-ethyl]-4-iodo-benzamide;
188	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-fluoro-benzyl)-4-iodo-N-methyl-benzamide;
189	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-chloro-benzyl)-4-iodo-N-methyl-benzamide;
190	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-dichloro-phenyl)-ethyl]-4-trifluoromethyl-benzamide;
191	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-N-methyl-4-trifluoromethyl-benzamide;
192	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-fluoro-benzyl)-N-methyl-4-trifluoromethyl-benzamide;
193	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-chloro-benzyl)-N-methyl-4-trifluoromethyl-benzamide;
194	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-fluoro-phenyl)-ethyl]-N-methyl-4-trifluoromethyl-benzamide;
195	(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-methyl-N-(1-phenyl-ethyl)-4-trifluoromethyl-benzamide;
196	(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-dichloro-phenyl)-ethyl]-4-fluoro-benzamide;
197	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-fluoro-N-methyl-benzamide; and
198	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-fluoro-N-[1-(4-fluoro-phenyl)-ethyl]-N-methyl-benzamide.

29. A pharmaceutical composition comprising a suitable amount of inert pharmaceutically acceptable diluent and a pharmaceutically efficacious amount of a compound of formula (I):



(I)

wherein

R^1 and R^2 are each independently selected from the group consisting of

a) H, C_{1-7}alkyl, C_{2-7}alkenyl, C_{2-7}alkynyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkenyl, benzo-fusedC_{4-7}cycloalkyl where the point of attachment is a carbon atom adjacent to the ring junction, C_{3-7}cycloalkylC_{1-7}alkyl,

b) naphthyl-(CR^s_2)-, benzoylC_{0-3}alkyl-(CR^s_2)-, phenyl, said phenyl optionally fused at two adjacent carbon atoms to R^f, phenyl-(CR^s_2)-, said phenyl optionally fused at two adjacent carbon atoms to R^f,

R^f is a linear 3- to 5-membered hydrocarbon moiety having 0 or 1 unsaturated bonds and having 0, 1 or 2 carbon members which is a carbonyl,

c) Ar^6-(CR^s_2)-, where Ar^6 is a 6-membered heteroaryl having carbon as a point of attachment, having 1 or 2 heteroatom members which are -N= and optionally benzo fused or pyrido fused,

d) Ar^5-(CR^s_2)-, where Ar^5 is a 5-membered heteroaryl having carbon as a point of attachment, having 1 heteroatom member selected from the group consisting of O, S, >NH or >NC_{1-4}alkyl, having 0 or 1 additional heteroatom member which is -N= and optionally benzo fused or pyrido fused,

e) Ar^{6-6}-(CR^s_2)-, where Ar^{6-6} is phenyl having the point of attachment and fused to a 6-membered heteroaryl having 1 or 2 heteroatom members which are –N=,

f) Ar^{6-5}-(CR^s_2)-, where Ar^{6-5} is phenyl having the point of attachment and fused to a 5-membered heteroaryl having 1 heteroatom member selected from the group consisting of O, S, >NH or >NC_{1-4}alkyl and having 0 or 1 additional heteroatom member which is -N=,

g) C_{1-4}alkylO- and HSC_{1-4}alkyl,

where R^1 and R^2 are not simultaneously H and, except in positions where R^s is indicated, each of a) to g) is substituted with 0, 1, 2, or 3 of R^q,

R^q is independently selected from the group consisting of C_{1-4}alkyl, hydroxy, fluoro, chloro, bromo, iodo, trifluoromethyl, aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkyl, diC_{1-4}alkylaminoC_{1-4}alkyl, HO-C_{1-4}alkyl, C_{1-4}alkylO-C_{1-4}alkyl, HS-C_{1-4}alkyl, C_{1-4}alkylS-C_{1-4}alkyl, C_{1-4}alkoxy and C_{1-4}alkylS-,

R^s is independently selected from the group consisting of hydrogen, C_{1-4}alkyl, trifluoromethyl, aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkyl, diC_{1-4}alkylaminoC_{1-4}alkyl, HO-C_{1-4}alkyl, HS-C_{1-4}alkyl, C_{1-4}alkylS-C_{1-4}alkyl and phenyl;

or, alternatively,

R^1 and R^2 may be taken together with the nitrogen to which they are attached and are selected from the group consisting of

i) 10-Oxa-4-aza-tricyclo[5.2.1.$0^{2,6}$]dec-4-yl, optionally mono- or di-substituted with R^p,

R^p is independently selected from the group consisting of hydroxy, C_{1-4}alkyl, hydroxyC_{1-4}alkyl, phenyl, mono-, di- or tri-halo substituted phenyl and hydroxyphenyl,

ii) a 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR^p, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, optionally having one carbon member which forms a bridge and having 0, 1 or 2 substituents R^p,

iii) a benzo fused 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR^p, having 0 or 1 additional unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, having

0, 1, 2, or 3 halo substituents on the benzene ring only and having 0, 1 or 2 substituents R^p,

iv) a 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR^p, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and optionally having one carbon member which forms a bridge, the heterocyclic ring fused at two adjacent carbon atoms forming a saturated bond or an adjacent carbon and nitrogen atom forming a saturated bond to a 4-7 membered hydrocarbon ring, having 0 or 1 possibly additional heteroatom member, not at the ring junction, selected from O, S, -N=, >NH or >NR^p, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and having 0, 1 or 2 substituents R^p;

v) 8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl, optionally having 0, 1 or 2 substituents R^p;

R^a is, independently, selected from the group consisting of -C_{1-6}alkyl, -C_{2-6}alkenyl, -C_{3-6}cycloalkyl, phenyl, furanyl, thienyl, benzyl, pyrrol-1-yl, -OH, -OC_{1-6}alkyl, -OC_{3-6}cycloalkyl, -Ophenyl, -Obenzyl, -SH, -SC_{1-6}alkyl, -SC_{3-6}cycloalkyl, -Sphenyl, -Sbenzyl, -CN, -NO_2, -$N(R^y)R^z$ (wherein R^y and R^z are independently selected from H, C_{1-4}alkyl or C_{1-6}cycloalkylC_{1-4}alkyl), -(C=O)C_{1-4}alkyl, -SCF_3, halo, -CF_3, -OCF_3, and -$COOC_{1-4}$alkyl, or, alternatively, two adjacent R^a, may be taken together with the carbons of attachment to form a fused ring and selected from the group consisting of phenyl, pyridyl and pyrimidinyl;

R^b is, independently, selected from the group consisting of -C_{1-4}alkyl and halogen;

and enantiomers, diastereomers, hydrates, solvates and pharmaceutically acceptable salts, esters and amides thereof.

30. A method for treating or preventing CCK2 mediated disease states comprising administering to a mammal in need of such treatment or prevention an effective dose of a compound of formula (I):



(I)

wherein

R^1 and R^2 are each independently selected from the group consisting of

a) H, C_{1-7}alkyl, C_{2-7}alkenyl, C_{2-7}alkynyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkenyl, benzo-fusedC_{4-7}cycloalkyl where the point of attachment is a carbon atom adjacent to the ring junction, C_{3-7}cycloalkylC_{1-7}alkyl,

b) naphthyl-(CR^s_2)-, benzoylC_{0-3}alkyl-(CR^s_2)-, phenyl, said phenyl optionally fused at two adjacent carbon atoms to R^f, phenyl-(CR^s_2)-, said phenyl optionally fused at two adjacent carbon atoms to R^f,

R^f is a linear 3- to 5-membered hydrocarbon moiety having 0 or 1 unsaturated bonds and having 0, 1 or 2 carbon members which is a carbonyl,

c) Ar^6-(CR^s_2)-, where Ar^6 is a 6-membered heteroaryl having carbon as a point of attachment, having 1 or 2 heteroatom members which are -N= and optionally benzo fused or pyrido fused,

d) Ar^5-(CR^s_2)-, where Ar^5 is a 5-membered heteroaryl having carbon as a point of attachment, having 1 heteroatom member selected from the group consisting of O, S, >NH or >NC_{1-4}alkyl, having 0 or 1 additional heteroatom member which is -N= and optionally benzo fused or pyrido fused,

e) Ar^{6-6}-(CR^s_2)-, where Ar^{6-6} is phenyl having the point of attachment and fused to a 6-membered heteroaryl having 1 or 2 heteroatom members which are –N=,

f) Ar^{6-5}-(CR^s_2)-, where Ar^{6-5} is phenyl having the point of attachment and fused to a 5-membered heteroaryl having 1 heteroatom member selected from the group consisting of O, S, >NH or >NC_{1-4}alkyl and having 0 or 1 additional heteroatom member which is -N=,

g) C_{1-4}alkylO- and HSC_{1-4}alkyl,

where R^1 and R^2 are not simultaneously H and, except in positions where R^s is indicated, each of a) to g) is substituted with 0, 1, 2, or 3 of R^q,

R^q is independently selected from the group consisting of C_{1-4}alkyl, hydroxy, fluoro, chloro, bromo, iodo, trifluoromethyl, aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkyl, diC_{1-4}alkylaminoC_{1-4}alkyl, HO-C_{1-4}alkyl, C_{1-4}alkylO-C_{1-4}alkyl, HS-C_{1-4}alkyl, C_{1-4}alkylS-C_{1-4}alkyl, C_{1-4}alkoxy and C_{1-4}alkylS-,

R^s is independently selected from the group consisting of hydrogen, C_{1-4}alkyl, trifluoromethyl, aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkyl, diC_{1-4}alkylaminoC_{1-4}alkyl, HO-C_{1-4}alkyl, HS-C_{1-4}alkyl, C_{1-4}alkylS-C_{1-4}alkyl and phenyl;

or, alternatively,

R^1 and R^2 may be taken together with the nitrogen to which they are attached and are selected from the group consisting of

i) 10-Oxa-4-aza-tricyclo[5.2.1.$0^{2,6}$]dec-4-yl, optionally mono- or di-substituted with R^p,

R^p is independently selected from the group consisting of hydroxy, C_{1-4}alkyl, hydroxyC_{1-4}alkyl, phenyl, mono-, di- or tri-halo substituted phenyl and hydroxyphenyl,

ii) a 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR^p, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, optionally having one carbon member which forms a bridge and having 0, 1 or 2 substituents R^p,

iii) a benzo fused 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the

nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR^p, having 0 or 1 additional unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, having 0, 1, 2, or 3 halo substituents on the benzene ring only and having 0, 1 or 2 substituents R^p,

iv) a 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR^p, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and optionally having one carbon member which forms a bridge, the heterocyclic ring fused at two adjacent carbon atoms forming a saturated bond or an adjacent carbon and nitrogen atom forming a saturated bond to a 4-7 membered hydrocarbon ring, having 0 or 1 possibly additional heteroatom member, not at the ring junction, selected from O, S, -N=, >NH or >NR^p, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and having 0, 1 or 2 substituents R^p;

v) 8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl, optionally having 0, 1 or 2 substituents R^p;

R^a is, independently, selected from the group consisting of -C_{1-6}alkyl, -C_{2-6}alkenyl, -C_{3-6}cycloalkyl, phenyl, furanyl, thienyl, benzyl, pyrrol-1-yl, -OH, -OC_{1-6}alkyl, -OC_{3-6}cycloalkyl, -Ophenyl, -Obenzyl, -SH, -SC_{1-6}alkyl, -SC_{3-6}cycloalkyl, -Sphenyl, -Sbenzyl, -CN, -NO_2, -$N(R^y)R^z$ (wherein R^y and R^z are independently selected from H, C_{1-4}alkyl or C_{1-6}cycloalkylC_{1-4}alkyl), -(C=O)C_{1-4}alkyl, -SCF_3, halo, -CF_3, -OCF_3, and -$COOC_{1-4}$alkyl, or, alternatively, two adjacent R^a, may be taken together with the carbons of attachment to form a fused ring and selected from the group consisting of phenyl, pyridyl and pyrimidinyl;

R^b is, independently, selected from the group consisting of -C_{1-4}alkyl and halogen;

and enantiomers, diastereomers, hydrates, solvates and pharmaceutically acceptable salts, esters and amides thereof.

31. A method for treating or preventing pancreatic adenocarcinoma, pain, eating disorders, gastro-esophageal reflux disease, gastroduodenal ulcers, reflux esophagitis, anxiety, colon cancer, peptic ulcers, pancreatic tumors, gastric tumors, Barrett's esophagus, antral G cell hyperplasia, pernicious anaemia and Zollinger-Ellison syndrome comprising administering to a mammal in need of such treatment or prevention an effective dose of a compound of formula (I):



(I)

wherein

R^1 and R^2 are each independently selected from the group consisting of

a) H, C_{1-7}alkyl, C_{2-7}alkenyl, C_{2-7}alkynyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkenyl, benzo-fusedC_{4-7}cycloalkyl where the point of attachment is a carbon atom adjacent to the ring junction, C_{3-7}cycloalkylC_{1-7}alkyl,

b) naphthyl-(CR^s_2)-, benzoylC_{0-3}alkyl-(CR^s_2)-, phenyl, said phenyl optionally fused at two adjacent carbon atoms to R^f, phenyl-(CR^s_2)-, said phenyl optionally fused at two adjacent carbon atoms to R^f,

R^f is a linear 3- to 5-membered hydrocarbon moiety having 0 or 1 unsaturated bonds and having 0, 1 or 2 carbon members which is a carbonyl,

c) Ar^6-(CR^s_2)-, where Ar^6 is a 6-membered heteroaryl having carbon as a point of attachment, having 1 or 2 heteroatom members which are -N= and optionally benzo fused or pyrido fused,

d) Ar^5-(CR^s_2)-, where Ar^5 is a 5-membered heteroaryl having carbon as a point of attachment, having 1 heteroatom member selected from the group consisting of O, S, >NH or >NC_{1-4}alkyl, having 0 or 1 additional

heteroatom member which is -N= and optionally benzo fused or pyrido fused,

e) Ar^{6-6}-(CR^s_2)-, where Ar^{6-6} is phenyl having the point of attachment and fused to a 6-membered heteroaryl having 1 or 2 heteroatom members which are –N=,

f) Ar^{6-5}-(CR^s_2)-, where Ar^{6-5} is phenyl having the point of attachment and fused to a 5-membered heteroaryl having 1 heteroatom member selected from the group consisting of O, S, >NH or >NC_{1-4}alkyl and having 0 or 1 additional heteroatom member which is -N=,

g) C_{1-4}alkylO- and HSC_{1-4}alkyl,

where R^1 and R^2 are not simultaneously H and, except in positions where R^s is indicated, each of a) to g) is substituted with 0, 1, 2, or 3 of R^q,

R^q is independently selected from the group consisting of C_{1-4}alkyl, hydroxy, fluoro, chloro, bromo, iodo, trifluoromethyl, aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkyl, diC_{1-4}alkylaminoC_{1-4}alkyl, HO-C_{1-4}alkyl, C_{1-4}alkylO-C_{1-4}alkyl, HS-C_{1-4}alkyl, C_{1-4}alkylS-C_{1-4}alkyl, C_{1-4}alkoxy and C_{1-4}alkylS-,

R^s is independently selected from the group consisting of hydrogen, C_{1-4}alkyl, trifluoromethyl, aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkyl, diC_{1-4}alkylaminoC_{1-4}alkyl, HO-C_{1-4}alkyl, HS-C_{1-4}alkyl, C_{1-4}alkylS-C_{1-4}alkyl and phenyl;

or, alternatively,

R^1 and R^2 may be taken together with the nitrogen to which they are attached and are selected from the group consisting of

i) 10-Oxa-4-aza-tricyclo[5.2.1.$0^{2,6}$]dec-4-yl, optionally mono- or di-substituted with R^p,

R^p is independently selected from the group consisting of hydroxy, C_{1-4}alkyl, hydroxyC_{1-4}alkyl, phenyl, mono-, di- or tri-halo substituted phenyl and hydroxyphenyl,

ii) a 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR^p, having 0, 1 or 2 unsaturated bonds, having 0, 1

or 2 carbon members which is a carbonyl, optionally having one carbon member which forms a bridge and having 0, 1 or 2 substituents R^p,

iii) a benzo fused 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR^p, having 0 or 1 additional unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, having 0, 1, 2, or 3 halo substituents on the benzene ring only and having 0, 1 or 2 substituents R^p,

iv) a 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR^p, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and optionally having one carbon member which forms a bridge, the heterocyclic ring fused at two adjacent carbon atoms forming a saturated bond or an adjacent carbon and nitrogen atom forming a saturated bond to a 4-7 membered hydrocarbon ring, having 0 or 1 possibly additional heteroatom member, not at the ring junction, selected from O, S, -N=, >NH or >NR^p, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and having 0, 1 or 2 substituents R^p;

v) 8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl, optionally having 0, 1 or 2 substituents R^p;

R^a is, independently, selected from the group consisting of -C_{1-6}alkyl, -C_{2-6}alkenyl, -C_{3-6}cycloalkyl, phenyl, furanyl, thienyl, benzyl, pyrrol-1-yl, -OH, -OC_{1-6}alkyl, -OC_{3-6}cycloalkyl, -Ophenyl, -Obenzyl, -SH, -SC_{1-6}alkyl, -SC_{3-6}cycloalkyl, -Sphenyl, -Sbenzyl, -CN, -NO_2, -N(R^y)R^z (wherein R^y and R^z are independently selected from H, C_{1-4}alkyl or C_{1-6}cycloalkylC_{1-4}alkyl), -(C=O)C_{1-4}alkyl, -SCF_3, halo, -CF_3, -OCF_3, and -COOC_{1-4}alkyl, or, alternatively, two adjacent R^a, may be taken together with the carbons of

attachment to form a fused ring and selected from the group consisting of phenyl, pyridyl and pyrimidinyl;

R^b is, independently, selected from the group consisting of -C_{1-4}alkyl and halogen;

and enantiomers, diastereomers, hydrates, solvates and pharmaceutically acceptable salts, esters and amides thereof.

32. A method for treating or preventing pancreatic adenocarcinoma, pain, gastro-esophageal reflux disease, gastroduodenal ulcers, reflux esophagitis, anxiety, colon cancer, peptic ulcers, pancreatic tumors and gastric tumors comprising administering to a mammal in need of such treatment or prevention an effective dose of a compound of formula (I):



(I)

wherein

R^1 and R^2 are each independently selected from the group consisting of

a) H, C_{1-7}alkyl, C_{2-7}alkenyl, C_{2-7}alkynyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkenyl, benzo-fusedC_{4-7}cycloalkyl where the point of attachment is a carbon atom adjacent to the ring junction, C_{3-7}cycloalkylC_{1-7}alkyl,

b) naphthyl-(CR^s_2)-, benzoylC_{0-3}alkyl-(CR^s_2)-, phenyl, said phenyl optionally fused at two adjacent carbon atoms to R^f, phenyl-(CR^s_2)-, said phenyl optionally fused at two adjacent carbon atoms to R^f,

R^f is a linear 3- to 5-membered hydrocarbon moiety having 0 or 1 unsaturated bonds and having 0, 1 or 2 carbon members which is a carbonyl,

c) Ar^6-(CR^s_2)-, where Ar^6 is a 6-membered heteroaryl having carbon as a point of attachment, having 1 or 2 heteroatom members which are -N= and optionally benzo fused or pyrido fused,

d) Ar^5-(CR^s_2)-, where Ar^5 is a 5-membered heteroaryl having carbon as a point of attachment, having 1 heteroatom member selected from the group consisting of O, S, >NH or >NC_{1-4}alkyl, having 0 or 1 additional heteroatom member which is -N= and optionally benzo fused or pyrido fused,

e) Ar^{6-6}-(CR^s_2)-, where Ar^{6-6} is phenyl having the point of attachment and fused to a 6-membered heteroaryl having 1 or 2 heteroatom members which are –N=,

f) Ar^{6-5}-(CR^s_2)-, where Ar^{6-5} is phenyl having the point of attachment and fused to a 5-membered heteroaryl having 1 heteroatom member selected from the group consisting of O, S, >NH or >NC_{1-4}alkyl and having 0 or 1 additional heteroatom member which is -N=,

g) C_{1-4}alkylO- and HSC_{1-4}alkyl,

where R^1 and R^2 are not simultaneously H and, except in positions where R^s is indicated, each of a) to g) is substituted with 0, 1, 2, or 3 of R^q,

R^q is independently selected from the group consisting of C_{1-4}alkyl, hydroxy, fluoro, chloro, bromo, iodo, trifluoromethyl, aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkyl, diC_{1-4}alkylaminoC_{1-4}alkyl, HO-C_{1-4}alkyl, C_{1-4}alkylO-C_{1-4}alkyl, HS-C_{1-4}alkyl, C_{1-4}alkylS-C_{1-4}alkyl, C_{1-4}alkoxy and C_{1-4}alkylS-,

R^s is independently selected from the group consisting of hydrogen, C_{1-4}alkyl, trifluoromethyl, aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkyl, diC_{1-4}alkylaminoC_{1-4}alkyl, HO-C_{1-4}alkyl, HS-C_{1-4}alkyl, C_{1-4}alkylS-C_{1-4}alkyl and phenyl;

or, alternatively,

R^1 and R^2 may be taken together with the nitrogen to which they are attached and are selected from the group consisting of

i) 10-Oxa-4-aza-tricyclo[5.2.1.$0^{2,6}$]dec-4-yl, optionally mono- or di-substituted with R^p,

R^p is independently selected from the group consisting of hydroxy, C_{1-4}alkyl, hydroxyC_{1-4}alkyl, phenyl, mono-, di- or tri-halo substituted phenyl and hydroxyphenyl,

ii) a 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR^p, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, optionally having one carbon member which forms a bridge and having 0, 1 or 2 substituents R^p,

iii) a benzo fused 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR^p, having 0 or 1 additional unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, having 0, 1, 2, or 3 halo substituents on the benzene ring only and having 0, 1 or 2 substituents R^p,

iv) a 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR^p, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and optionally having one carbon member which forms a bridge, the heterocyclic ring fused at two adjacent carbon atoms forming a saturated bond or an adjacent carbon and nitrogen atom forming a saturated bond to a 4-7 membered hydrocarbon ring, having 0 or 1 possibly additional heteroatom member, not at the ring junction, selected from O, S, -N=, >NH or >NR^p, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and having 0, 1 or 2 substituents R^p;

v) 8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl, optionally having 0, 1 or 2 substituents R^p;

R^a is, independently, selected from the group consisting of -C_{1-6}alkyl, -C_{2-6}alkenyl, -C_{3-6}cycloalkyl, phenyl, furanyl, thienyl, benzyl, pyrrol-1-yl, -OH, -OC_{1-6}alkyl, -OC_{3-6}cycloalkyl, -Ophenyl, -Obenzyl, -SH, -SC_{1-6}alkyl, -SC_{3-6}cycloalkyl, -Sphenyl, -Sbenzyl, -CN, -NO_2, -$N(R^y)R^z$ (wherein R^y and R^z are independently selected from H, C_{1-4}alkyl or C_{1-6}cycloalkylC_{1-4}alkyl), -$(C=O)C_{1-4}$alkyl, -SCF_3, halo, -CF_3, -OCF_3, and -$COOC_{1-4}$alkyl, or, alternatively, two adjacent R^a, may be taken together with the carbons of attachment to form a fused ring and selected from the group consisting of phenyl, pyridyl and pyrimidinyl;

R^b is, independently, selected from the group consisting of -C_{1-4}alkyl and halogen;

and enantiomers, diastereomers, hydrates, solvates and pharmaceutically acceptable salts, esters and amides thereof.